Financial Disclosure

Oracle's Ellison Cancels Stock Sale Plan, No Shares Sold

Image
Oracle's Ellison Cancels Stock Sale Plan, No Shares Sold

Austin, Texas – September 17, 2026 -- Oracle Corporation (NYSE: ORCL) confirmed that Executive Chair and Chief Technology Officer Larry Ellison has cancelled his 10b5-1 trading plan to sell company stock, halting a scheduled divestment before any shares changed hands.

Ellison cancels stock sale plan with zero shares sold

Oracle stated no stock was sold under the now-terminated 10b5-1 plan. The company added that Ellison currently has no other arrangements in place to sell any of his Oracle shares.

White Memorial Hospitals Generate $1.2B Economic Impact in L.A.

Image
White Memorial Hospitals Generate $1.2B Economic Impact in L.A.

Los Angeles – September 17, 2026 -- Adventist Health White Memorial and Adventist Health White Memorial Montebello generate more than $1.2 billion in annual economic activity and support approximately 5,500 jobs across Los Angeles County, according to a new study.

Study quantifies hospitals' role as economic anchors serving 2.4 million residents

The analysis, conducted by the Los Angeles County Economic Development Corporation (LAEDC), examined the two hospitals' functions as healthcare providers, employers, and community anchors. Combined, they serve more than 2.4 million residents across their primary and secondary service areas.

EscapeSquid Seeks $2.5M Seed to Link Virtual Cycling With Travel

Image
EscapeSquid Seeks $2.5M Seed to Link Virtual Cycling With Travel

Newark, Del. – September 17, 2026 -- Xanh Entertainment Inc. is pursuing a $2.5 million seed funding round to scale EscapeSquid, its platform linking virtual stationary cycling with fitness studios, local events and destination travel.

Xanh Entertainment targets $2.5 million to build fitness-to-travel infrastructure

John Phung, Founder and CEO of Xanh Entertainment Inc., said the proposed seed round is intended to fund technology development and partnerships across fitness, hospitality and travel sectors. The capital would support a model designed to move participants from at-home virtual rides into studio classes, local experiences, regional events and destination travel.

Devonian Health Group to List on NYSE American Under 'DHGR'

Image
Devonian Health Group to List on NYSE American Under 'DHGR'

Quebec – September 17, 2026 -- Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) expects its common shares and warrants to begin trading on NYSE American LLC as early as September 17, 2026, under the ticker symbols "DHGR" and "DHGR WS."

Devonian pursues dual listing tied to underwritten public offering

The proposed NYSE American listing is connected to an underwritten public offering of Devonian's common shares and warrants. The company will retain its existing listing on the TSX Venture Exchange and has reserved the symbol "DHGR" there, with plans to later change its TSXV ticker from "GSD" to "DHGR."

Listing remains contingent on NYSE American's final authorization

Trading commencement on NYSE American depends on market conditions and final approval of Devonian's listing application, as well as the company's continued compliance with exchange rules.

CID Capital Acquires Kaiser Garage Doors in Third Fund IV Deal

Image
CID Capital Acquires Kaiser Garage Doors in Third Fund IV Deal

Nashville, Tenn. – September 17, 2026 -- XLCS Partners, Inc. served as buyside advisor to CID Capital on its investment in Kaiser Garage Doors & Gates, LLC, a deal that closed on September 17, 2026.

CID Capital completes third platform investment from its latest fund

The Kaiser transaction marks the third platform investment from CID Capital Opportunity Fund IV, L.P. CID Capital, based in Indianapolis, Indiana, is a private equity firm that takes control positions in lower middle market companies, focusing on founder- and family-owned businesses.

Kaiser brings 30-plus years of regional operations across Arizona

Headquartered in Tucson, Arizona, Kaiser installs and services residential and commercial overhead doors and gates across the Phoenix, Tucson, and White Mountains markets. The company has built its footprint over more than three decades, establishing long-standing customer relationships in the region.

CordenPharma Invests €80M to Reach 500M Sterile Injectable Units

Image
CordenPharma Invests €80M to Reach 500M Sterile Injectable Units

Basel – September 17, 2026 -- CordenPharma is committing €80 million in multi-year capital expenditure to expand aseptic fill-finish capacity at its FDA- and EMA-approved Caponago site near Milan, targeting total production capacity of up to 500 million sterile injectable units annually.

New 11,000-square-meter facility adds over 50% to site footprint

A key milestone within the total investment was the €13 million acquisition of a new 11,000 m2 commercial building and an adjacent 26,000 m2 plot next to the existing advanced-phase fill-finish area. The expansion, completed September 17, 2026, increases the facility's overall footprint by more than 50%.

PlanetiQ Wins Spot on NOAA's New $Multi-Year SBEM Satellite Data Contract

Image
PlanetiQ Wins Spot on NOAA's New $Multi-Year SBEM Satellite Data Contract

Golden, Colo. – September 17, 2026 -- PlanetiQ has been named an industry partner under NOAA's new Space-Based Environmental Monitoring (SBEM) Indefinite Delivery, Indefinite Quantity contract, a vehicle running from September 17, 2026, through September 17, 2026, with a five-year base period and a five-year option.

NOAA opens new decade-long contract vehicle for commercial satellite data

The SBEM IDIQ, established by NOAA's National Environmental Satellite, Data, and Information Service (NESDIS) through its Commercial Data Program, will let PlanetiQ compete for task orders covering two data types: Global Navigation Satellite System-Radio Occultation (GNSS-RO) observations for atmospheric and ionospheric monitoring, and thermospheric neutral density data for satellite orbit prediction.

o15 Capital Exits $31M Facility After Simplify Compliance Unit Sale

Image
o15 Capital Exits $31M Facility After Simplify Compliance Unit Sale

Atlanta – – September 17, 2026 -- o15 Capital Partners has successfully exited a $31 million senior secured credit facility provided to Simplify Compliance Holdings, LLC through its Emerging America Credit Opportunities fund and affiliates. Repayment followed the sale of Simplify's datacenterHawk business unit to S&P Global.

o15 realizes full repayment on $31 million facility backing Leeds Equity-owned Simplify

Simplify Compliance Holdings, a diversified provider of B2B training, events and subscription information, is backed by Leeds Equity Partners. The credit facility supported the Company's strategic objectives and Leeds Equity's value creation initiatives across Simplify's compliance, workforce training, and data and information businesses.

Butler National Posts Record Q1 Revenue, Up 53% to $30.8 Million

Image
Butler National Posts Record Q1 Revenue, Up 53% to $30.8 Million

New Century, Kansas – September 17, 2026 -- Butler National Corporation (OTCQX: BUKS) reported first-quarter fiscal 2027 revenue of $30.8 million, up 53% from the prior-year period, driven by a surge in aircraft modification work and a record aerospace backlog.

Net income climbs 43% to $5.3 million as operating margin expands to 24%

Operating income rose 59% to $7.4 million, while net income increased 43% to $5.3 million for the quarter ended September 17, 2026. Earnings per share rose to $0.08 from $0.06 a year earlier, reflecting margin expansion from 23% to 24%.

Eli Lilly Closes Acquisition of AtaiBeckley, Gains Depression Drug BPL-003

Image
Eli Lilly Closes Acquisition of AtaiBeckley, Gains Depression Drug BPL-003

Indianapolis – September 17, 2026 -- Eli Lilly and Company (NYSE: LLY) has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions.

Deal adds BPL-003 to Lilly's neuroscience pipeline for treatment-resistant depression

The acquisition brings Lilly control of AtaiBeckley's lead investigational program, BPL-003, targeting patients with treatment-resistant depression who have not responded to multiple prior therapies. AtaiBeckley shareholders approved the transaction at a special meeting held ahead of closing.